Cargando…

Treatment use in prognostic model research: a systematic review of cardiovascular prognostic studies

BACKGROUND: Ignoring treatments in prognostic model development or validation can affect the accuracy and transportability of models. We aim to quantify the extent to which the effects of treatment have been addressed in existing prognostic model research and provide recommendations for the handling...

Descripción completa

Detalles Bibliográficos
Autores principales: Pajouheshnia, Romin, Damen, Johanna A. A. G., Groenwold, Rolf H. H., Moons, Karel G. M., Peelen, Linda M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460846/
https://www.ncbi.nlm.nih.gov/pubmed/31093544
http://dx.doi.org/10.1186/s41512-017-0015-0
_version_ 1783410394997456896
author Pajouheshnia, Romin
Damen, Johanna A. A. G.
Groenwold, Rolf H. H.
Moons, Karel G. M.
Peelen, Linda M.
author_facet Pajouheshnia, Romin
Damen, Johanna A. A. G.
Groenwold, Rolf H. H.
Moons, Karel G. M.
Peelen, Linda M.
author_sort Pajouheshnia, Romin
collection PubMed
description BACKGROUND: Ignoring treatments in prognostic model development or validation can affect the accuracy and transportability of models. We aim to quantify the extent to which the effects of treatment have been addressed in existing prognostic model research and provide recommendations for the handling and reporting of treatment use in future studies. METHODS: We first describe how and when the use of treatments by individuals in a prognostic study can influence the development or validation of a prognostic model. We subsequently conducted a systematic review of the handling and reporting of treatment use in prognostic model studies in cardiovascular medicine. Data on treatment use (e.g. medications, surgeries, lifestyle interventions), the timing of their use, and the handling of such treatment use in the analyses were extracted and summarised. RESULTS: Three hundred two articles were included in the review. Treatment use was not mentioned in 91 (30%) articles. One hundred forty-six (48%) reported specific information about treatment use in their studies; 78 (26%) provided information about multiple treatments. Three articles (1%) reported changes in medication use (“treatment drop-in”) during follow-up. Seventy-nine articles (26%) excluded treated individuals from their analysis, 80 articles (26%) modelled treatment as an outcome, and of the 155 articles that developed a model, 86 (55%) modelled treatment use, almost exclusively at baseline, as a predictor. CONCLUSIONS: The use of treatments has been partly considered by the majority of CVD prognostic model studies. Detailed accounts including, for example, information on treatment drop-in were rare. Where relevant, the use of treatments should be considered in the analysis of prognostic model studies, particularly when a prognostic model is designed to guide the use of certain treatments and these treatments have been used by the study participants. Future prognostic model studies should clearly report the use of treatments by study participants and consider the potential impact of treatment use on the study findings. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s41512-017-0015-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6460846
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64608462019-05-15 Treatment use in prognostic model research: a systematic review of cardiovascular prognostic studies Pajouheshnia, Romin Damen, Johanna A. A. G. Groenwold, Rolf H. H. Moons, Karel G. M. Peelen, Linda M. Diagn Progn Res Review BACKGROUND: Ignoring treatments in prognostic model development or validation can affect the accuracy and transportability of models. We aim to quantify the extent to which the effects of treatment have been addressed in existing prognostic model research and provide recommendations for the handling and reporting of treatment use in future studies. METHODS: We first describe how and when the use of treatments by individuals in a prognostic study can influence the development or validation of a prognostic model. We subsequently conducted a systematic review of the handling and reporting of treatment use in prognostic model studies in cardiovascular medicine. Data on treatment use (e.g. medications, surgeries, lifestyle interventions), the timing of their use, and the handling of such treatment use in the analyses were extracted and summarised. RESULTS: Three hundred two articles were included in the review. Treatment use was not mentioned in 91 (30%) articles. One hundred forty-six (48%) reported specific information about treatment use in their studies; 78 (26%) provided information about multiple treatments. Three articles (1%) reported changes in medication use (“treatment drop-in”) during follow-up. Seventy-nine articles (26%) excluded treated individuals from their analysis, 80 articles (26%) modelled treatment as an outcome, and of the 155 articles that developed a model, 86 (55%) modelled treatment use, almost exclusively at baseline, as a predictor. CONCLUSIONS: The use of treatments has been partly considered by the majority of CVD prognostic model studies. Detailed accounts including, for example, information on treatment drop-in were rare. Where relevant, the use of treatments should be considered in the analysis of prognostic model studies, particularly when a prognostic model is designed to guide the use of certain treatments and these treatments have been used by the study participants. Future prognostic model studies should clearly report the use of treatments by study participants and consider the potential impact of treatment use on the study findings. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s41512-017-0015-0) contains supplementary material, which is available to authorized users. BioMed Central 2017-09-26 /pmc/articles/PMC6460846/ /pubmed/31093544 http://dx.doi.org/10.1186/s41512-017-0015-0 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Pajouheshnia, Romin
Damen, Johanna A. A. G.
Groenwold, Rolf H. H.
Moons, Karel G. M.
Peelen, Linda M.
Treatment use in prognostic model research: a systematic review of cardiovascular prognostic studies
title Treatment use in prognostic model research: a systematic review of cardiovascular prognostic studies
title_full Treatment use in prognostic model research: a systematic review of cardiovascular prognostic studies
title_fullStr Treatment use in prognostic model research: a systematic review of cardiovascular prognostic studies
title_full_unstemmed Treatment use in prognostic model research: a systematic review of cardiovascular prognostic studies
title_short Treatment use in prognostic model research: a systematic review of cardiovascular prognostic studies
title_sort treatment use in prognostic model research: a systematic review of cardiovascular prognostic studies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460846/
https://www.ncbi.nlm.nih.gov/pubmed/31093544
http://dx.doi.org/10.1186/s41512-017-0015-0
work_keys_str_mv AT pajouheshniaromin treatmentuseinprognosticmodelresearchasystematicreviewofcardiovascularprognosticstudies
AT damenjohannaaag treatmentuseinprognosticmodelresearchasystematicreviewofcardiovascularprognosticstudies
AT groenwoldrolfhh treatmentuseinprognosticmodelresearchasystematicreviewofcardiovascularprognosticstudies
AT moonskarelgm treatmentuseinprognosticmodelresearchasystematicreviewofcardiovascularprognosticstudies
AT peelenlindam treatmentuseinprognosticmodelresearchasystematicreviewofcardiovascularprognosticstudies